0000899243-21-025984.txt : 20210625 0000899243-21-025984.hdr.sgml : 20210625 20210625170046 ACCESSION NUMBER: 0000899243-21-025984 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210412 FILED AS OF DATE: 20210625 DATE AS OF CHANGE: 20210625 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wallace Owen B. CENTRAL INDEX KEY: 0001778843 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40522 FILM NUMBER: 211048791 MAIL ADDRESS: STREET 1: C/O FULCRUM THERAPEUTICS, INC. STREET 2: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Monte Rosa Therapeutics, Inc. CENTRAL INDEX KEY: 0001826457 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 645 SUMMER STREET STREET 2: SUITE 102 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 617-949-2643 MAIL ADDRESS: STREET 1: 645 SUMMER STREET STREET 2: SUITE 102 CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-04-12 0 0001826457 Monte Rosa Therapeutics, Inc. GLUE 0001778843 Wallace Owen B. MONTE ROSA THERAPEUTICS, INC. 645 SUMMER STREET, SUITE 102 BOSTON MA 02210 0 1 0 0 Chief Scientific Officer Stock Option (Right to Buy) 6.14 2021-04-12 4 A 0 387069 0.00 A 2031-04-12 Common Stock 387069 387069 D Stock Option (Right to Buy) 19.00 2021-06-23 4 A 0 113298 0.00 A 2031-06-22 Common Stock 113298 113298 D On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The securities covered by such transaction were previously included on the Reporting Person's Form 3. 25% of this option shall vest and become exercisable on February 8, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. 25% of this option shall vest and become exercisable on May 28, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. /s/ Ajim Tamboli, Attorney-in-Fact 2021-06-25